Muz has been involved in clinical research for over 17 years, across all phases of clinical drug development. Following his academic research on improving early diagnosis in lung cancer, he moved into industry, working on clinical trials across a range of therapeutic areas. He has held various, operationally focused roles primarily on early phase clinical development programmes at Parexel, Roche and AstraZeneca. Following completion of his Executive MBA from the University of Cambridge in 2018 with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development” he took on the role of Director, Clinical Program Operations in the Exploratory Medicine Pharmacology group at Eli Lilly where he was lucky enough to lead the operational delivery of the First in Human study on their Covid-19 Antibody programme. Muz is the Therapeutic Area lead for Vaccines and Infectious Diseases at Medable, providing cross-functional support to help translate DCT capabilities into clinical operational delivery.